Ultragenyx Pharmaceutical is acquiring exclusive global rights to Abeona Therapeutics’ investigational adeno-associated virus (AAV) gene therapy ABO-102.
The data was inadequate to conclude that the drug was effective in preventing disease progression, FDA noted.